Related Experiment Video
Updated: May 19, 2026
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Juvenile idiopathic arthritis: management and therapeutic options
Insights
Juvenile Idiopathic Arthritis (JIA) treatment has advanced with targeted therapies like TNF inhibitors, improving outcomes. Further research is needed on the long-term safety and effects of these innovative biologic treatments for children.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Pharmacology
Background:
- Juvenile Idiopathic Arthritis (JIA) treatment aims to suppress inflammation, achieve remission, alleviate pain, and maintain function with minimal toxicity.
- Recent advancements in classification, assessment tools, remission definitions, imaging, and gene expression profiling have driven the development of targeted JIA therapies.
Purpose of the Study:
- To review the evolution of treatment strategies for Juvenile Idiopathic Arthritis (JIA).
- To highlight the impact of new targeted therapies on managing childhood arthritis.
Main Methods:
- Review of recent discoveries and advancements in JIA treatment over the past 10-15 years.
- Discussion of traditional treatments (NSAIDs, intra-articular steroids, methotrexate) and their limitations.
- Exploration of novel biologic targeted therapies, including TNFα inhibitors, IL-1/IL-6 blockade, and B-cell blockade.
Main Results:
- Nonsteroidal anti-inflammatory agents and intra-articular steroids remain relevant for mild or oligoarticular JIA.
- Methotrexate shows efficacy but is insufficient for many patients, necessitating advanced treatments.
- Biologic targeted therapies, such as TNF inhibitors, have transformed JIA management.
Conclusions:
- Biologic targeted therapies represent a significant shift in treating pediatric JIA.
- Long-term effects and safety profiles of these advanced biologic treatments require further investigation.
Abstract:
THE GOALS OF TREATMENT FOR JUVENILE IDIOPATHIC ARTHRITIS (JIA) INCLUDE: suppression of inflammation, achievement of remission, relief of pain, maintenance of function and doing so with minimal toxicity. Important discoveries over the past 10-15 years have led to more targeted treatments for children with JIA. The International League of Associations for Rheumatology (ILAR) classification system for childhood arthritides, better assessment tools for clinical response, improved definitions of remission, new imaging techniques and evidence in gene expression profiling have all contributed to the development of more targeted treatments. Nonsteroidal anti-inflammatory agents still have a role in mild disease and intra-articular steroid injections continue to be used most commonly in patients with oligoarticular JIA. Disease-modifying agents such as methotrexate have demonstrated efficacy and safety; however, in many patients, the disease remains active despite this treatment. These children now receive more targeted treatment including the tumor necrosis factor alpha (TNFα) inhibitors, interleukin-1 blockade, interleukin-6 blockade, selective costimulation modulators and selective B-cell blockade. The biologic targeted therapies have changed the strategy in which we treat our children with JIA; however, there remains much to be learned about the long-term effects and safety of these medicines.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Rheumatic Heart Disease III: Medical Management
01:17Pericarditis III: Medical Management
01:14Myocarditis III: Medical Management
01:20Rheumatic Heart Disease IV: Nursing Management
01:26Tonsillitis II: Management